{"resourceType":"ValueSet","id":"2.16.840.1.113883.3.3616.200.110.102.1014","meta":{"versionId":"5","lastUpdated":"2022-07-13T01:02:20.000-04:00","profile":["http://hl7.org/fhir/StructureDefinition/shareablevalueset","http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"]},"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/valueset-author","valueString":"Clinical Architecture"},{"url":"http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate","valueDate":"2023-06-21"},{"url":"http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate","valueDate":"2022-07-13"}],"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3616.200.110.102.1014","identifier":[{"system":"urn:ietf:rfc:3986","value":"urn:oid:2.16.840.1.113883.3.3616.200.110.102.1014"}],"version":"20220713","name":"CasirivimabImdevimabAdministration","title":"Casirivimab / Imdevimab Administration","status":"retired","experimental":false,"date":"2023-06-21T18:16:37-04:00","publisher":"Clinical Architecture","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"US"}]}],"purpose":"(Clinical Focus: This set of values contains terms related to intravenous or subcutaneous administration of casirivimab / imdevimab.),(Data Element Scope: ),(Inclusion Criteria: Includes terms related to intravenous or subcutaneous administration of casirivimab / imdevimab.),(Exclusion Criteria: )","compose":{"include":[{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","concept":[{"code":"M0240","display":"Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses"},{"code":"M0241","display":"Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency, subsequent repeat doses"},{"code":"M0243","display":"Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring"},{"code":"M0244","display":"Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency"},{"code":"Q0240","display":"Injection, casirivimab and imdevimab, 600 mg"},{"code":"Q0243","display":"Injection, casirivimab and imdevimab, 2400 mg"},{"code":"Q0244","display":"Injection, casirivimab and imdevimab, 1200 mg"}]}]},"expansion":{"identifier":"urn:uuid:004ccbe5-e0cb-4fc6-813b-531eec1220af","timestamp":"2023-12-11T01:34:07-05:00","total":7,"contains":[{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"M0240","display":"Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"M0241","display":"Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency, subsequent repeat doses"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"M0243","display":"Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"M0244","display":"Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"Q0240","display":"Injection, casirivimab and imdevimab, 600 mg"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"Q0243","display":"Injection, casirivimab and imdevimab, 2400 mg"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"Q0244","display":"Injection, casirivimab and imdevimab, 1200 mg"}]}}